コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 follow-up visits for 6 months (all by their pharmacist).
2 personnel remained blinded except the local pharmacist.
3 greater; blinding was known only to the site pharmacist.
4 a drug accountability auditor, and the site pharmacist.
5 e treatment assignment, except for the study pharmacist.
6 However, PEFR data were not provided to the pharmacist.
7 research nurse, a physician, and a clinical pharmacist.
8 identity to the masked staff by an unmasked pharmacist.
9 purchasing patterns and alert physicians and pharmacists.
10 professors and its repeated use in training pharmacists.
11 itals should consider employing clinical ICU pharmacists.
12 rding to the absence or presence of clinical pharmacists.
13 comprising infectious disease physicians and pharmacists.
14 nurses, 30 school first aiders, 30 community pharmacists.
16 mple opportunities to implement the program, pharmacists accessed patient-specific data only about ha
24 nt education; (3) collaborative care between pharmacist and primary care provider/cardiologist; and (
26 care interventions recommended by a clinical pharmacist and to specifically examine cost savings (or
27 trospectively evaluated by a physician and 2 pharmacists and a factor likely related to the error was
28 cted by self-report stimulated by nurses and pharmacists and by daily chart review, and were classifi
29 cted by stimulated self-report by nurses and pharmacists and by daily review of all charts by nurse i
32 ription through its evaluation by practicing pharmacists and pharmacy professors and its repeated use
33 dialysis establish dosing guidelines for all pharmacists and physicians to follow to provide consiste
34 Patients and all study personnel, except for pharmacists and statisticians, were masked to treatment
35 ere reviewed for references to critical care pharmacists and their role on the multiprofessional crit
36 isted of a primary care general internist, a pharmacist, and a nurse or other certified diabetes educ
38 en the treating elder care physician and the pharmacist, and implementation of medication changes.
40 on of drugs is limited to oncology-certified pharmacists, and administration to chemotherapy-certifie
41 d medication education, regular follow-up by pharmacists, and medications dispensed in time-specific
43 of no greater than 1:2, adding critical care pharmacists, and providing dedicated respiratory therapi
44 ists, pharmaceutical scientists, physicians, pharmacists, and regulatory specialists to explore strat
45 e practitioner, physician assistant, nurses, pharmacists, and student members of the Society of Criti
46 e intervention arm will visit with the study pharmacist approximately 1 week post-hospital discharge.
47 In the UK, doctors, dentists, coroners, and pharmacists are allowed to report through the yellow car
51 ized skills characterizing the critical care pharmacist as clinician, educator, researcher, and manag
52 d skills that characterize the critical care pharmacist as clinician, educator, researcher, and manag
55 he prospective cohort were identified by the pharmacist at the patient's first clinic visit (1.1 erro
58 Group assignment was not masked from study pharmacists, but allocation was concealed from participa
59 were faxed to the antimicrobial stewardship pharmacist by noon each day in order to evaluate empiric
60 an off-site team: a nurse care manager and a pharmacist by telephone, and a psychologist and a psychi
62 opriate use of antibiotics and what role the pharmacist can play in ensuring the optimal use of infec
64 vascular care, including the use of clinical pharmacists, can efficiently deliver high-quality care.
66 ved home BP monitoring and Web training plus pharmacist care had a greater net reduction in systolic
68 ng and secure patient Web site training plus pharmacist care management delivered through Web communi
70 atients were randomized to usual care (usual pharmacist care with no specific intervention) or interv
73 including nurses, case managers, physicians, pharmacists, case workers, dietitians, physical therapis
74 fectious disease specialists (physicians and pharmacists), clinical microbiologists, and infection co
75 of this study was to evaluate if a physician/pharmacist collaborative model would be implemented as d
77 ssisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and
79 zed trial of CVD risk reduction by community pharmacists, demonstrating a significant reduction in ri
80 ian assistants, nurses, nurse practitioners, pharmacists, dentists, dental hygienists, occupational t
81 es, nurse prescribers, Physician Assistants, pharmacists, dieticians, and physical or occupational th
82 e 24-wk study period, the pediatric clinical pharmacist documented all interventions that occurred du
85 fied included appropriate patient selection, pharmacist-driven patient education, and pharmacist-led
86 versus MALDI-TOF MS combined with real-time, pharmacist-driven, antimicrobial stewardship (AMS) inter
90 computer alert appeared on the screen to the pharmacist entering the order, who could then consult th
93 rovided information and met with a community pharmacist for scheduled visits at baseline, 3, 6, 9, an
96 es were defined as having at least a partial pharmacist full-time equivalent specifically devoted to
97 reaction assay, with physician education and pharmacist guidance, did not significantly reduce excess
103 ludes an infectious disease specialist and a pharmacist in addition to the burn surgeon is highly rec
105 e average time spent per day by the clinical pharmacist in the pediatric intensive care unit was 0.73
108 nsmission among drug-using patients and that pharmacists in most states have a clear or reasonable le
111 to support the potential role of nurses and pharmacists in the effective management of chronic pain.
112 atient characteristics, presence of clinical pharmacists in the ICU (odds ratio [OR], 0.67; 95% CI, 0
113 tation of protocols and presence of clinical pharmacists in the ICU, and close collaboration between
114 igators (two physicians, two nurses, and one pharmacist) in adult ICU patient encounters (n = 192).
115 makers should consider an expanded role for pharmacists, including prescribing, to address the burde
116 alert sent to the covering provider and unit pharmacist indicating new acute kidney injury) or usual
118 is study was to document the impact of daily pharmacist interventions on clinical outcomes of intensi
119 d by 5.3% (CI, 2.6% to 7.6%; P < 0.001), and pharmacist interventions to prevent error were reduced b
120 y readmission rate to the study institution, pharmacist interventions to prevent error, drug-drug int
123 sk for medication errors and that transplant pharmacist involvement leads to improved safety through
128 on, pharmacist-driven patient education, and pharmacist-led adverse event and adherence monitoring.
129 tise can achieve substantial returns through pharmacist-led antimicrobial stewardship programmes and
132 To determine the effectiveness and harms of pharmacist-led chronic disease management for community-
133 tates and of any design reported outcomes of pharmacist-led chronic disease management versus a compa
136 nd medical record extraction compared with a pharmacist-led comprehensive medication assessment.
137 ultivariable adjustment, association between pharmacist-led education and dabigatran adherence was no
138 patient selection was performed at 31 sites, pharmacist-led education was provided at 30 sites, and p
139 feedback for at-risk patients (control) or a pharmacist-led information technology intervention (PINC
140 tensification of Medications intervention, a pharmacist-led intervention combining elements found in
141 ntervention comprises 4 main components: (1) pharmacist-led medication reconciliation and tailoring;
142 , 1.14; 95% CI, 1.05-1.25), and provision of pharmacist-led monitoring (RR, 1.25; 95% CI, 1.11-1.41)
147 t, and formally review interventions made by pharmacists, locum arrangements, and the workload of jun
151 8 countries among experts including hospital pharmacists, microbiologists, and infectious disease spe
152 laboratory staff were masked, but the study pharmacist (MK), vaccine administrator, and study statis
153 ce to the active drug; the study physicians, pharmacists, monitors, and patients remained masked duri
155 rviews were conducted with doctors (n = 10), pharmacists (n = 10), and nurses and midwives (n = 19) i
157 ntervention included: real-time MALDI-TOF MS pharmacist notification and prospective AMS provider fee
158 dres of health-care professionals, including pharmacists, nurses, and community health workers, to me
159 sults immediately to the pharmacy and alerts pharmacists of potential interventions, and (ii) the edu
161 intervention by infectious disease clinical pharmacists on the basis of the results of tests for mec
162 her and when, during their interactions with pharmacists or salespeople, the discounts specified in S
164 systematic medication titration by doctors, pharmacists, or patients; education; or lifestyle counse
167 ocation was not masked to general practices, pharmacists, patients, or researchers who visited practi
169 ounds that included a respiratory therapist, pharmacist, physician and nurse; and protocol use as hav
176 n = 64, mean rate 3.0 per patient); however, pharmacists prevented 119 of these errors (1.9 errors pe
178 lthcare professionals (e.g. doctors, nurses, pharmacists, radiographers etc.) and others involved in
181 k, were reviewed, with 7934 interventions by pharmacists recorded for the five targeted measures, sug
184 asked to treatment assignment apart from the pharmacist responsible for preparing the study treatment
187 linary committee of oncologists, nurses, and pharmacists reviewed the chemotherapy use process and id
188 vides background information on the clinical pharmacist's role, training, certification, and potentia
189 usion, we have found evidence that community pharmacists, school first aiders and primary care nurses
192 ce, patients received standardized HIV nurse/pharmacist support, which included nurse visits and tele
193 was sourced from a panel survey of hospital pharmacists, surgeons, and theatre nurses who are involv
194 ded telephone nurse care managers, telephone pharmacists, telepsychologists, and telepsychiatrists.
195 ceutical care were more satisfied with their pharmacist than the usual care group (P =.03) and the PE
196 pment, supplies and personnel, and dedicated pharmacist time for blood culture review and of making i
198 utions may enhance the preparation of future pharmacists to contribute to effective antimicrobial ste
199 efforts to overcome these barriers, allowing pharmacists to deliver high-quality patient care to the
201 d 1998, of educational outreach by community pharmacists to influence physician prescribing in Englan
202 hthalmologists should work with insurers and pharmacists to prevent such discontinuation of use as ge
203 ed that a formal, consistent intervention by pharmacists to promote adherence to our institution's se
208 ts were randomly assigned (1:1) by the trial pharmacist, using previously generated treatment allocat
210 cipation in these programs by physicians and pharmacists varies by state, and funding for continuatio
211 xt allocation was obtained by the study site pharmacist via an interactive voice-response system.
212 An infectious disease and/or critical care pharmacist was contacted with the microarray assay resul
213 fection studied, the involvement of clinical pharmacists was evaluated in 8,927-54,042 patients from
214 suggest that team-based care using clinical pharmacists was implemented in diverse primary care offi
216 ity rates in ICUs that did not have clinical pharmacists were higher by 23.6% (p < 0.001, 386 extra d
219 ants who received treatment and the research pharmacist who implemented the randomisation and provide
220 to the treatment assignment, except for the pharmacist who prepared the ISIS-APO(a)Rx or placebo.
221 to treatment assignment, except for the site pharmacist who prepared the study drug but had no intera
222 e BP telemonitors and transmitted BP data to pharmacists who adjusted antihypertensive therapy accord
225 ted a survey of the instructions provided by pharmacists, who play an important role in educating pat
227 ior patterns; pharmacy, integrating clinical pharmacist with direct attending support; laboratory, en
228 ealth professionals that includes a clinical pharmacist with expertise in optimal and comprehensive m
230 armaceutical care program (n = 447) provided pharmacists with recent patient-specific clinical data (
231 s triggered telephone calls to physicians by pharmacists with training in geriatrics, whereby princip
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。